PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY

• E. Jabbour,
• G. Martinelli,
• M. Vignetti,
• H. Kantarjian,
• D. Gomez-Almaguer,
• Y. Minami,
• H. Dombret,
• M. Hennessy,
• A. Vorog,
• B. Wang,
• J.-M. Ribera

Affiliations

E. Jabbour

1 The University of Texas, MD Anderson Cancer Center, Houston, TX, United States of America

G. Martinelli

2 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”- IRST S.r.l, Meldola

M. Vignetti

3 GIMEMA Research Foundation, Rome, Italy

H. Kantarjian

4 The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America

D. Gomez-Almaguer

5 Hospital Universitario, UANL, Monterrey, Nuevo Leon, Mexico

Y. Minami

6 National Cancer Center Hospital East, Kashiwa, Japan

H. Dombret

7 Institut de Recherche Saint-Louis, Université de Paris, Hôpital Sain-Louis, Paris, France

M. Hennessy

8 Takeda Development Center Americas, Inc., Lexington, MA, United States of America

A. Vorog

8 Takeda Development Center Americas, Inc., Lexington, MA, United States of America

B. Wang

8 Takeda Development Center Americas, Inc., Lexington, MA, United States of America

J.-M. Ribera

9 Institut Català d’Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Badalona, Spain